Sunshine Biopharma Inc. (SBFMW) stock
SBFMWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SBFM
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 10/30
$0.03+0.00 (+2.00%)
Close on Oct 30, 2026Market cap $11.36MP/E –Yield –
Sunshine Biopharma gross margin
Gross margin is gross profit as a percentage of revenue.
Sunshine Biopharma's gross margin for the twelve months ending Jun 30, 2026 was 30.3%. For fiscal 2025 it was 33.8%, against 30.6% the year before. The highest annual figure on record is 63.8% in fiscal 2020.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 33.8% | +3.2 |
| FY2024 | Dec 31, 2024 | 30.6% | −4.0 |
| FY2023 | Dec 31, 2023 | 34.6% | −4.4 |
| FY2022 | Dec 31, 2022 | 39.0% | −9.4 |
| FY2021 | Dec 31, 2021 | 48.4% | −15.4 |
| FY2020 | Dec 31, 2020 | 63.8% | +16.1 |
| FY2019 | Dec 31, 2019 | 47.7% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 26.2% | −10.2 |
| Q1 FY2026 | Mar 31, 2026 | 27.0% | −3.7 |
| Q4 FY2025 | Dec 31, 2025 | 35.3% | +3.1 |
| Q3 FY2025 | Sep 30, 2025 | 32.6% | −1.3 |
| Q2 FY2025 | Jun 30, 2025 | 36.4% | +11.0 |
| Q1 FY2025 | Mar 31, 2025 | 30.7% | −0.5 |
| Q4 FY2024 | Dec 31, 2024 | 32.2% | −1.2 |
| Q3 FY2024 | Sep 30, 2024 | 34.0% | +0.6 |
| Q2 FY2024 | Jun 30, 2024 | 25.3% | −9.8 |
| Q1 FY2024 | Mar 31, 2024 | 31.2% | −6.1 |
| Q4 FY2023 | Dec 31, 2023 | 33.4% | −4.4 |
| Q3 FY2023 | Sep 30, 2023 | 33.4% | −17.1 |
| Q2 FY2023 | Jun 30, 2023 | 35.1% | −15.2 |
| Q1 FY2023 | Mar 31, 2023 | 37.4% | −13.9 |
| Q4 FY2022 | Dec 31, 2022 | 37.8% | +9.9 |
| Q3 FY2022 | Sep 30, 2022 | 50.5% | −10.8 |
| Q2 FY2022 | Jun 30, 2022 | 50.3% | −14.7 |
| Q1 FY2022 | Mar 31, 2022 | 51.2% | −2.6 |
| Q4 FY2021 | Dec 31, 2021 | 28.0% | −34.7 |
| Q3 FY2021 | Sep 30, 2021 | 61.3% | −1.8 |
| Q2 FY2021 | Jun 30, 2021 | 65.0% | −0.9 |
| Q1 FY2021 | Mar 31, 2021 | 53.8% | −11.3 |
| Q4 FY2020 | Dec 31, 2020 | 62.6% | +2.3 |
| Q3 FY2020 | Sep 30, 2020 | 63.0% | +35.3 |
| Q2 FY2020 | Jun 30, 2020 | 65.9% | +14.1 |
| Q1 FY2020 | Mar 31, 2020 | 65.0% | +19.4 |
| Q4 FY2019 | Dec 31, 2019 | 60.4% | +70.9 |
| Q3 FY2019 | Sep 30, 2019 | 27.8% | – |
| Q2 FY2019 | Jun 30, 2019 | 51.9% | – |
| Q1 FY2019 | Mar 31, 2019 | 45.6% | – |
| Q1 FY2018 | Mar 31, 2018 | -10.6% | – |